1
Home
Companies

Indaptus Therapeutics

Indaptus Therapeutics
Leadership team

Mr. Jeffrey A. Meckler (CEO & Director)

Dr. Michael J. Newman Ph.D. (Founder, Chief Scientific Officer & Director)

Mr. Walt Addison Linscott Esq. (Chief Bus. Officer)

Products/ Services
Health Care, Medical, Medical Device
Number of Employees
0 - 50
Headquarters
New York, New York, United States
Established
2000
Company Registration
SEC CIK number: 0001857044
Traded as
NASDAQ:INDP
URL
https://indaptusrx.com
Overview
Location

Summary
History
Mission
Vision
Key Team
Recognition and Award
References
Summary
Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as chronic hepatitis B virus and human immunodeficiency virus infection, which is in Phase I clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is based in New York, New York.
History

Indaptus was founded in 2017 by a team of scientists, engineers, and healthcare professionals committed to advancing gene therapy treatments. Our team has decades of experience in the biopharmaceutical industry and has actively led the development of many of today’s leading gene therapy products.

Mission
Our mission is to transform lives by creating innovative, curative, and cost-effective gene therapy treatments that address unmet therapeutic needs.
Vision
Our vision is to revolutionize how diseases are treated, enabling more people to lead healthier, longer lives.
Key Team

Mr. Nir Sassi (CFO, Sec. & Treasurer)

Recognition and Awards
Indaptus has received numerous awards and accolades over the past few years, including the AIconics Innovation Award, the Best Technologies Award, and the Silver in the 2020 Fierce 15 Awards. We have also been recognized by the United Nations for our commitment to social responsibility and sustainable development.
References

https://in.investing.com/equities/intec-pharma

https://finance.yahoo.com/quote/INDP/profile?p=INDP

https://www.crunchbase.com/organization/indaptus-therapeutics

https://indaptusrx.com

Dive deeper into fresh insights across Business, Industry Leaders and Influencers, Organizations, Education, and Investors for a comprehensive view.

Indaptus Therapeutics
Leadership team

Mr. Jeffrey A. Meckler (CEO & Director)

Dr. Michael J. Newman Ph.D. (Founder, Chief Scientific Officer & Director)

Mr. Walt Addison Linscott Esq. (Chief Bus. Officer)

Products/ Services
Health Care, Medical, Medical Device
Number of Employees
0 - 50
Headquarters
New York, New York, United States
Established
2000
Company Registration
SEC CIK number: 0001857044
Traded as
NASDAQ:INDP
URL
https://indaptusrx.com